CBIO
HealthcareCrescent Biopharma, Inc.
$11.27-0.29 (-2.55%)
Prev Close
$11.56
Open
$11.69
High
$12.39
Low
$11.20
Volume
84.5K
Market Cap
$333.7M
P/E
—
Div Yield
—
Buys (12M)
0
$0.00
Sells (12M)
0
$0.00
Net Activity
Net Buyer
$0.00
Active Insiders
0
last 12 mo
CBIO Price Chart
CBIO Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 9, 2024↗ | Invus Public Equities, L.P. | Sell | 322,361 | $0.19 | $61.2K | 6,578,440 | |
| Aug 7, 2024↗ | Invus Public Equities, L.P. | Sell | 220,255 | $0.19 | $41.2K | 6,695,660 | |
| Aug 5, 2024↗ | Invus Public Equities, L.P. | Sell | 349,764 | $0.20 | $71.1K | 7,146,380 | |
| Jul 30, 2024↗ | Invus Public Equities, L.P. | Sell | 1,379,119 | $0.23 | $315.3K | 8,330,730 | |
| Jun 24, 2024↗ | Rock Edwin | Chief Medical Officer | Buy | 305,000 | $0.26 | $78.8K | 680,403 |
| Jun 20, 2024↗ | Hahn Brian M. | SVP Finance, CFO | Buy | 17,500 | $0.25 | $4.3K | 70,643 |
| Sep 25, 2023↗ | Rock Edwin | Chief Medical Officer | Buy | 65,403 | $1.38 | $90.3K | 375,403 |
| May 18, 2023↗ | Hahn Brian M. | SVP Finance, CFO | Sell | 3,700 | $1.95 | $7.2K | 53,143 |
| May 11, 2023↗ | JUNIUS DANIEL M | Director | Buy | 30,000 | $1.56 | $46.8K | 93,250 |
| May 9, 2023↗ | Johnson Bruce S | SVP & Chief Commercial Officer | Buy | 13,500 | $1.57 | $21.2K | 138,980 |
| Feb 28, 2023↗ | Invus Public Equities, L.P. | 10% Owner | Buy | 100,000 | $1.70 | $170.0K | 8,589,060 |
| Feb 23, 2023↗ | Invus Public Equities, L.P. | 10% Owner | Buy | 400,000 | $1.78 | $712.3K | 8,489,060 |
| Feb 17, 2023↗ | Invus Public Equities, L.P. | 10% Owner | Buy | 1,515,266 | $2.00 | $3.03M | 8,089,060 |
| Feb 13, 2023↗ | Invus Public Equities, L.P. | 10% Owner | Buy | 11,451 | $3.24 | $37.1K | 6,573,800 |
| Jan 27, 2023↗ | SANDELL SCOTT D | 10% Owner | Sell | 3,652,016 | $3.14 | $11.48M | 4,379,240 |
| Jan 6, 2023↗ | SANDELL SCOTT D | 10% Owner | Sell | 71,362 | $2.76 | $196.9K | 4,737,610 |
| Jan 4, 2023↗ | SANDELL SCOTT D | 10% Owner | Sell | 398,133 | $2.98 | $1.19M | 4,928,970 |
| Dec 27, 2022↗ | Rock Edwin | Chief Medical Officer | Buy | 110,000 | $2.25 | $247.5K | 310,000 |
| Nov 18, 2022↗ | JUNIUS DANIEL M | Director | Buy | 20,000 | $1.87 | $37.4K | 63,250 |
| Nov 16, 2022↗ | Rock Edwin | Chief Medical Officer | Buy | 200,000 | $1.55 | $309.0K | 200,000 |
| Nov 14, 2022↗ | Girard Armand | SVP, Chief Business Officer | Buy | 6,500 | $1.05 | $6.8K | 29,161 |
| Nov 14, 2022↗ | Hahn Brian M. | SVP Finance, CFO | Buy | 20,000 | $1.06 | $21.2K | 56,843 |
| Nov 14, 2022↗ | Magnani John L. | SVP of Research, CSO | Buy | 45,045 | $1.17 | $52.7K | 366,078 |
| Nov 14, 2022↗ | PEARSON TIMOTHY R | Director | Buy | 19,400 | $1.29 | $25.0K | 24,650 |
| Nov 14, 2022↗ | Semerjian Harout | Chief Executive Officer | Buy | 25,000 | $1.29 | $32.3K | 25,000 |
| Mar 10, 2022↗ | Girard Armand | SVP, Chief Business Officer | Sell | 2,339 | $1.09 | $2.5K | 22,661 |
| Mar 10, 2022↗ | Hahn Brian M. | SVP Finance, CFO | Sell | 2,917 | $1.09 | $3.2K | 36,843 |
| Mar 10, 2022↗ | Magnani John L. | SVP of Research, CSO | Sell | 3,227 | $1.09 | $3.5K | 321,033 |
| Nov 18, 2021↗ | Andrews Patricia S | Director | Buy | 40,000 | $2.05 | $82.0K | 45,250 |
CBIO Insider Buying Activity
The following table shows recent insider purchases of Crescent Biopharma, Inc. (CBIO) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 24, 2024↗ | Rock Edwin | Chief Medical Officer | Buy | 305,000 | $0.26 | $78.8K | 680,403 |
| Jun 20, 2024↗ | Hahn Brian M. | SVP Finance, CFO | Buy | 17,500 | $0.25 | $4.3K | 70,643 |
| Sep 25, 2023↗ | Rock Edwin | Chief Medical Officer | Buy | 65,403 | $1.38 | $90.3K | 375,403 |
| May 11, 2023↗ | JUNIUS DANIEL M | Director | Buy | 30,000 | $1.56 | $46.8K | 93,250 |
| May 9, 2023↗ | Johnson Bruce S | SVP & Chief Commercial Officer | Buy | 13,500 | $1.57 | $21.2K | 138,980 |
| Feb 28, 2023↗ | Invus Public Equities, L.P. | 10% Owner | Buy | 100,000 | $1.70 | $170.0K | 8,589,060 |
| Feb 23, 2023↗ | Invus Public Equities, L.P. | 10% Owner | Buy | 400,000 | $1.78 | $712.3K | 8,489,060 |
| Feb 17, 2023↗ | Invus Public Equities, L.P. | 10% Owner | Buy | 1,515,266 | $2.00 | $3.03M | 8,089,060 |
| Feb 13, 2023↗ | Invus Public Equities, L.P. | 10% Owner | Buy | 11,451 | $3.24 | $37.1K | 6,573,800 |
| Dec 27, 2022↗ | Rock Edwin | Chief Medical Officer | Buy | 110,000 | $2.25 | $247.5K | 310,000 |
| Nov 18, 2022↗ | JUNIUS DANIEL M | Director | Buy | 20,000 | $1.87 | $37.4K | 63,250 |
| Nov 16, 2022↗ | Rock Edwin | Chief Medical Officer | Buy | 200,000 | $1.55 | $309.0K | 200,000 |
| Nov 14, 2022↗ | Girard Armand | SVP, Chief Business Officer | Buy | 6,500 | $1.05 | $6.8K | 29,161 |
| Nov 14, 2022↗ | Hahn Brian M. | SVP Finance, CFO | Buy | 20,000 | $1.06 | $21.2K | 56,843 |
| Nov 14, 2022↗ | Magnani John L. | SVP of Research, CSO | Buy | 45,045 | $1.17 | $52.7K | 366,078 |
| Nov 14, 2022↗ | PEARSON TIMOTHY R | Director | Buy | 19,400 | $1.29 | $25.0K | 24,650 |
| Nov 14, 2022↗ | Semerjian Harout | Chief Executive Officer | Buy | 25,000 | $1.29 | $32.3K | 25,000 |
| Nov 18, 2021↗ | Andrews Patricia S | Director | Buy | 40,000 | $2.05 | $82.0K | 45,250 |
CBIO Insider Selling Activity
The following table shows recent insider sales of Crescent Biopharma, Inc. (CBIO) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 9, 2024↗ | Invus Public Equities, L.P. | Sell | 322,361 | $0.19 | $61.2K | 6,578,440 | |
| Aug 7, 2024↗ | Invus Public Equities, L.P. | Sell | 220,255 | $0.19 | $41.2K | 6,695,660 | |
| Aug 5, 2024↗ | Invus Public Equities, L.P. | Sell | 349,764 | $0.20 | $71.1K | 7,146,380 | |
| Jul 30, 2024↗ | Invus Public Equities, L.P. | Sell | 1,379,119 | $0.23 | $315.3K | 8,330,730 | |
| May 18, 2023↗ | Hahn Brian M. | SVP Finance, CFO | Sell | 3,700 | $1.95 | $7.2K | 53,143 |
| Jan 27, 2023↗ | SANDELL SCOTT D | 10% Owner | Sell | 3,652,016 | $3.14 | $11.48M | 4,379,240 |
| Jan 6, 2023↗ | SANDELL SCOTT D | 10% Owner | Sell | 71,362 | $2.76 | $196.9K | 4,737,610 |
| Jan 4, 2023↗ | SANDELL SCOTT D | 10% Owner | Sell | 398,133 | $2.98 | $1.19M | 4,928,970 |
| Mar 10, 2022↗ | Girard Armand | SVP, Chief Business Officer | Sell | 2,339 | $1.09 | $2.5K | 22,661 |
| Mar 10, 2022↗ | Hahn Brian M. | SVP Finance, CFO | Sell | 2,917 | $1.09 | $3.2K | 36,843 |
| Mar 10, 2022↗ | Magnani John L. | SVP of Research, CSO | Sell | 3,227 | $1.09 | $3.5K | 321,033 |
CBIO Insiders
Similar Stocks to CBIO
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B